ArticleInsights into imaging2024
MRI analysis of relative tumor enhancement in liver metastases and correlation with immunohistochemical features.
Article in Insights into imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liver metastases beyond classical imaging findings.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInvestigate the association between the relative tumor enhancement (RTE) of gadoxetic acid across various MRI phases and immunohistochemical (IHC) features in patients with liver metastases (LM) from colorectal cancer (CRC), breast cancer (BC), and pancreatic cancer (PC).
methodsA retrospective analysis was conducted on 68 patients with LM who underwent 1.5-T MRI scans. Non-contrast and contrast-enhanced T1-weighted (T1-w) gradient echo (GRE) sequences were acquired before LM biopsy. RTE values among LM groups were compared by cancer type using analysis of variance. The relationships between RTE and IHC features tumor stroma ratio, cell count, Ki67 proliferation index, and CD45 expression were evaluated using Spearman's rank correlation coefficients.
resultsSignificant differences in RTE were observed across different MRI phases among patients with BCLM, CRCLM, and PCLM: arterial phase (0.75 ± 0.42, 0.37 ± 0.36, and 0.44 ± 0.19), portal venous phase (1.09 ± 0.41, 0.59 ± 0.44, and 0.53 ± 0.24), and venous phase (1.11 ± 0.45, 0.65 ± 0.61, and 0.50 ± 0.20). In CRCLM, RTE inversely correlated with mean Ki67 (r = -0.50, p = 0.01) in the hepatobiliary phase. Negative correlations between RTE and CD45 expression were found in PCLM and CRCLM in the portal venous phase (r = -0.69, p = 0.01 and r = -0.41, p = 0.04) and the venous phase (r = -0.65, p = 0.01 and r = -0.44, p = 0.02).
conclusionSignificant variations in RTE were identified among different types of LM, with correlations between RTE values and IHC markers such as CD45 and Ki67 suggesting that RTE may serve as a non-invasive biomarker for predicting IHC features in LM. CRITICAL RELEVANCE STATEMENT: RTE values serve as a predictive biomarker for IHC features in liver metastasis, potentially enhancing non-invasive patient assessment, disease monitoring, and treatment planning. KEY POINTS: Few studies link gadoxetic acid-enhanced MRI with immunohistochemistry in LM. RTE varies by liver metastasis type and correlates with CD45 and Ki67. RTE reflects IHC features in LM, aiding non-invasive assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.